Free Trial

ProShares Ultra Nasdaq Biotechnology Announces Quarterly Dividend of $0.13 (NASDAQ:BIB)

ProShares Ultra Nasdaq Biotechnology logo with background
Remove Ads

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) announced a quarterly dividend on Tuesday, March 25th, NASDAQ Dividends reports. Investors of record on Wednesday, March 26th will be paid a dividend of 0.1309 per share by the exchange traded fund on Tuesday, April 1st. This represents a $0.52 annualized dividend and a dividend yield of 1.05%. The ex-dividend date of this dividend is Wednesday, March 26th.

ProShares Ultra Nasdaq Biotechnology Stock Down 1.7 %

Shares of BIB traded down $0.88 during mid-day trading on Friday, reaching $50.11. 6,348 shares of the stock traded hands, compared to its average volume of 13,832. The stock has a fifty day simple moving average of $54.24 and a 200 day simple moving average of $57.25. ProShares Ultra Nasdaq Biotechnology has a 12-month low of $47.20 and a 12-month high of $69.56. The firm has a market cap of $59.13 million, a price-to-earnings ratio of 26.77 and a beta of 1.63.

About ProShares Ultra Nasdaq Biotechnology

(Get Free Report)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Featured Stories

Dividend History for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Should You Invest $1,000 in ProShares Ultra Nasdaq Biotechnology Right Now?

Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.

While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

5 International Stocks to Escape U.S. Market Volatility
MicroStrategy’s Bold Bitcoin Bet: Genius Move or Dangerous Gamble?
5 Big Reasons the S&P 500 Could Soar in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads